{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:56:17Z","timestamp":1762005377878,"version":"3.37.3"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"13th Five-Year Plan, Ministry of Science and Technology of China","award":["2018ZX10302-102"],"award-info":[{"award-number":["2018ZX10302-102"]}]},{"DOI":"10.13039\/501100009601","name":"Beijing Municipal Administration of Hospitals\u2019 Ascent Plan","doi-asserted-by":"crossref","award":["DFL20191802"],"award-info":[{"award-number":["DFL20191802"]}],"id":[{"id":"10.13039\/501100009601","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals\u2019 Clinical Medicine Development of Special Funding Support","doi-asserted-by":"crossref","award":["ZYLX202126"],"award-info":[{"award-number":["ZYLX202126"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the prevalence and characteristics of doravirine resistance and cross-resistance in patients who failed first-line ART in China.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>From 2014 to 2108, 4132 patients from five provinces were tested for drug resistance by genotypic resistance testing. Drug resistance mutations were assessed using the Stanford HIVdb algorithm Version 9.0. Sequences classified as having low-level, intermediate and high-level resistance were defined as having drug resistance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, the prevalence of doravirine and other NNRTIs cross-resistance was 69.5%, with intermediate and high-level resistance accounting for 56.4%. Doravirine resistance highly correlated with efavirenz (r = 0.720) and nevirapine (r = 0.721) resistance and moderately correlated with etravirine (r = 0.637) and rilpivirine (r = 0.692) resistance. The most frequent doravirine-associated resistance mutations were V106M (8.7%), K101E (6.8%) and P225H (5.1%). High-level resistance was mainly due to Y188L (3.2%) and M230L (2.7%). There were significant differences between genotypes and provinces. Compared with CRF01_AE, CRF07_BC (OR = 0.595, 95% CI = 0.546\u20130.648) and CRF08_BC (OR = 0.467, 95% CI = 0.407\u20130.536) were associated with lower risks of doravirine resistance. Conversely, genotype A (OR = 3.003, 95% CI = 1.806\u20134.991) and genotype B (OR = 1.250, 95% CI = 1.021\u20131.531) were associated with higher risks of doravirine resistance. The risk of doravirine resistance was significantly lower in Xinjiang compared with other provinces.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In China, the prevalence of doravirine cross-resistance among patients who have failed first-line ART is high. Therefore, doravirine should not be used blindly without genotypic resistance testing and is not recommended for people who have failed first-line NNRTI-based ART.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkac016","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T12:06:19Z","timestamp":1642421179000},"page":"1119-1124","source":"Crossref","is-referenced-by-count":10,"title":["Prevalence of doravirine cross-resistance in HIV-infected adults who failed first-line ART in China, 2014\u201318"],"prefix":"10.1093","volume":"77","author":[{"given":"Zhuoqun","family":"Sun","sequence":"first","affiliation":[{"name":"Peking University Ditan Teaching Hospital, Beijing, China"},{"name":"Capital Medical University Affiliated Beijing Ditan Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Lan","sequence":"additional","affiliation":[{"name":"Guangzhou Eighth People\u2019s Hospital, Guangzhou Medical University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujia","family":"Liang","sequence":"additional","affiliation":[{"name":"Guangxi Key Laboratory of Major Infectious Disease Prevention and Control and Biosafety Emergency Response, Guangxi Center for Disease Control and Prevention, Nanning, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Chongqing Public Health Medical Center, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingjian","family":"Ni","sequence":"additional","affiliation":[{"name":"Xinjiang Center for Disease Control and Prevention, Xinjiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Laboratory Science Department of Weifang Medical College, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengting","family":"Yu","sequence":"additional","affiliation":[{"name":"Capital Medical University Affiliated Beijing Ditan Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiling","family":"Chen","sequence":"additional","affiliation":[{"name":"Capital Medical University Affiliated Beijing Ditan Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanxi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Capital Medical University Affiliated Beijing Ditan Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1030-8298","authenticated-orcid":false,"given":"Liting","family":"Yan","sequence":"additional","affiliation":[{"name":"Capital Medical University Affiliated Beijing Ditan Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Cai","sequence":"additional","affiliation":[{"name":"Guangzhou Eighth People\u2019s Hospital, Guangzhou Medical University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanghua","family":"Lan","sequence":"additional","affiliation":[{"name":"Guangxi Key Laboratory of Major Infectious Disease Prevention and Control and Biosafety Emergency Response, Guangxi Center for Disease Control and Prevention, Nanning, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Ma","sequence":"additional","affiliation":[{"name":"National Center for AIDS\/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6386-9879","authenticated-orcid":false,"given":"Fujie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University Ditan Teaching Hospital, Beijing, China"},{"name":"Capital Medical University Affiliated Beijing Ditan Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"2022033111265193900_dkac016-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2009.10.002","article-title":"The development of antiretroviral therapy and its impact on the HIV-1\/AIDS pandemic","volume":"85","author":"Broder","year":"2010","journal-title":"Antiviral Res"},{"author":"WHO","key":"2022033111265193900_dkac016-B2"},{"author":"WHO","key":"2022033111265193900_dkac016-B3"},{"key":"2022033111265193900_dkac016-B4","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/hiv.13020","article-title":"Characteristics and viral suppression among people living with HIV from the National Free Antiretroviral Therapy Programme, 2019","volume":"21","author":"Zhao","year":"2020","journal-title":"HIV Med"},{"key":"2022033111265193900_dkac016-B5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1345\/aph.1M359","article-title":"Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents","volume":"44","author":"Adams","year":"2010","journal-title":"Ann Pharmacother"},{"key":"2022033111265193900_dkac016-B6","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.3390\/v6082960","article-title":"The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors","volume":"6","author":"Sluis-Cremer","year":"2014","journal-title":"Viruses"},{"key":"2022033111265193900_dkac016-B7","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1124\/pr.117.013706","article-title":"Adverse neuropsychiatric events and recreational use of efavirenz and other HIV-1 antiretroviral drugs","volume":"70","author":"Dalwadi","year":"2018","journal-title":"Pharmacol Rev"},{"key":"2022033111265193900_dkac016-B8","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/QAD.0b013e32835f1db0","article-title":"Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis","volume":"27","author":"Shubber","year":"2013","journal-title":"AIDS"},{"key":"2022033111265193900_dkac016-B9","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.2165\/0003495-200868160-00007","article-title":"Etravirine","volume":"68","author":"Deeks","year":"2008","journal-title":"Drugs"},{"key":"2022033111265193900_dkac016-B10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1468-1293.2012.00994.x","article-title":"Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest","volume":"13","author":"Girard","year":"2012","journal-title":"HIV Med"},{"key":"2022033111265193900_dkac016-B11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","article-title":"Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial","volume":"378","author":"Cohen","year":"2011","journal-title":"Lancet"},{"key":"2022033111265193900_dkac016-B12","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","article-title":"Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial","volume":"378","author":"Molina","year":"2011","journal-title":"Lancet"},{"key":"2022033111265193900_dkac016-B13","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/AAC.04201-14","article-title":"In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways","volume":"59","author":"Feng","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2022033111265193900_dkac016-B14","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/QAI.0000000000001031","article-title":"Rilpivirine and doravirine have complementary efficacies against NNRTI-resistant HIV-1 mutants","volume":"72","author":"Smith","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"author":"US FDA","key":"2022033111265193900_dkac016-B15"},{"key":"2022033111265193900_dkac016-B16","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1128\/AAC.02650-15","article-title":"Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations","volume":"60","author":"Feng","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022033111265193900_dkac016-B17","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/S2352-3018(18)30021-3","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"2022033111265193900_dkac016-B18","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/cid\/ciy540","article-title":"Doravirine\/lamivudine\/tenofovir disoproxil fumarate is non-inferior to efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial","volume":"68","author":"Orkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022033111265193900_dkac016-B19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/QAI.0000000000002056","article-title":"Switching to doravirine\/lamivudine\/tenofovir disoproxil fumarate (DOR\/3TC\/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT trial","volume":"81","author":"Johnson","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022033111265193900_dkac016-B20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jac\/dkt316","article-title":"Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing","volume":"69","author":"Melikian","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2022033111265193900_dkac016-B21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ijantimicag.2019.02.007","article-title":"Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors","volume":"53","author":"Sterrantino","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2022033111265193900_dkac016-B22","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/jac\/dkz553","article-title":"Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy","volume":"75","author":"Soulie","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2022033111265193900_dkac016-B23","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/17425255.2019.1673367","article-title":"Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment","volume":"15","author":"Wang","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2022033111265193900_dkac016-B24","doi-asserted-by":"crossref","first-page":"e48747","DOI":"10.1371\/journal.pone.0048747","article-title":"Molecular epidemiology of human immunodeficiency virus type 1 in Guangdong province of southern China","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS One"},{"key":"2022033111265193900_dkac016-B25","doi-asserted-by":"crossref","first-page":"e0243650","DOI":"10.1371\/journal.pone.0243650","article-title":"The genotype distribution, infection stage and drug resistance mutation profile of human immunodeficiency virus-1 among the infected blood donors from five Chinese blood centers, 2014-2017","volume":"15","author":"Liang","year":"2020","journal-title":"PLoS One"},{"key":"2022033111265193900_dkac016-B26","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41598-020-79951-2","article-title":"Patterns and risk of HIV-1 transmission network among men who have sex with men in Guangxi, China","volume":"11","author":"Pang","year":"2021","journal-title":"Sci Rep"},{"key":"2022033111265193900_dkac016-B27","doi-asserted-by":"crossref","first-page":"563180","DOI":"10.3389\/fpubh.2020.563180","article-title":"Associations between geodemographic factors and access to public health services among Chinese floating population","volume":"8","author":"Guan","year":"2020","journal-title":"Front Public Health"},{"key":"2022033111265193900_dkac016-B28","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3390\/ijerph18031096","article-title":"Regional disparity and patients mobility: benefits and spillover effects of the spatial network structure of the health services in China","volume":"18","author":"Fu","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"2022033111265193900_dkac016-B29","doi-asserted-by":"crossref","first-page":"28206","DOI":"10.1007\/s11356-018-2811-7","article-title":"Quality analysis and policy recommendations on the utilization of community basic public health services in urban and suburban Shanghai from 2009 to 2014","volume":"25","author":"Guo","year":"2018","journal-title":"Environ Sci Pollut Res Int"},{"key":"2022033111265193900_dkac016-B30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12939-020-1139-3","article-title":"The disequilibrium in the distribution of the primary health workforce among eight economic regions and between rural and urban areas in China","volume":"19","author":"Wang","year":"2020","journal-title":"Int J Equity Health"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/4\/1119\/43192743\/dkac016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/4\/1119\/43192743\/dkac016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T14:10:53Z","timestamp":1648735853000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/4\/1119\/6521537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2,3]]},"published-print":{"date-parts":[[2022,3,31]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac016","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2022,2,3]]}}}